ClinicalTrials.gg
CompletedNCT02497235Updated Sep 15, 2026Results posted

A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935

A Phase 1 interventional study of TAK-935 and [18F]MNI-792 (tracer) in Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents, sponsored by Takeda. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Takeda · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
19 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 793 studies in Epilepsy with a site in United States — 161 open to participants now, 194 under way, 17 of them phase 3. Epilepsy · United States.

Enrollment
470th of 588
11 · median 40
Started
2015
with 37 others
Phase 1
66 of 793
11 open now
Registered
382nd of 793
by date

Among the 793 studies in Epilepsy with a site in United States, this one is the 470th largest by enrollment of the 588 interventional ones that give a count, is one of 38 that started in 2015, is one of 66 in phase 1, and was the 382nd registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

161 of the 793 studies in Epilepsy with a site in United States are open now. Recruiting first, the newest first:

156 more — sign in →

All 161 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 282 Epilepsy studies recruiting now, 112 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 19 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 793 studies in Epilepsy with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the brain cholesterol 24S-hydroxylase (CH24H) enzyme occupancy of TAK-935 after single oral dose in healthy participants using the positron emission tomography (PET) ligand [18F]MNI-792 and PET imaging and to determine the relationship of occupancy to TAK-935 exposure.

Read the detailed description

The drug being tested in this study is called TAK-935. TAK-935 is being tested to examine the degree and duration of brain CH24H enzyme occupancy/target engagement as a function of TAK-935 plasma concentration in order to guide dosing and schedule for future clinical trials with TAK-935. This study will utilize the PET ligand [18F]MNI-792 to evaluate the brain CH24H occupancy of TAK-935 after single dose oral administration in healthy adult participants. The study will evaluate up to 16 participants. The first 2 participants will take TAK-935 600 mg oral solution and undergo PET imaging using tracer [18F]MNI-792 up to 5 mcg (up to 370 MBq), injection, intravenously prior to each PET scan at Baseline, 45 minutes and 10 hours post-TAK-935 dose. TAK-935 dose and timing of post-dose scans for subsequent participants will be based on the data from the previous participants. This single-center trial will be conducted in the United States. The overall time to participate in this study is up to 55 days. Participants will make 4 visits to the clinic, including 2 confinement periods to the clinic for PET imaging. Participants will be contacted by phone on Day 28 for follow-up safety assessments.

03

Conditions studied

  • Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents

Browse trials for

Keywords

  • Drug therapy, Positron Emission Tomography, Brain enzyme occupancy, Cholesterol 24S-hydroxylase, CH24H
04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In the opinion of the investigator, is capable of understanding and complying with protocol requirements.
  2. Signs and dates a written, form and any required privacy authorization prior to the initiation of any study procedures including requesting that a participant fast for any laboratory evaluations.
  3. Is a healthy male or female and aged 19 to 55 years, inclusive, at the time of informed consent and first study medication dose.
  4. Weighs at least 45 kilogram (kg) and has a (BMI) from 18.0 to 30.0 kilogram per square meter (kg/m\^2), inclusive at Screening.
  5. A female of non-bearing potential (example by history; or history of hysterectomy, bilateral salpingectomy, or oophorectomy).

Exclusion criteria

Exclusion Criteria:

  1. Have a known history or evidence of a disorder (including neurologic and psychiatric), or disease that in the opinion of the study investigator would pose a risk to the participant safety or interfere with the study evaluation, procedures or completion.
  2. to magnetic resonance imaging (MRI) based on the standard MRI radiography screening questionnaire.
  3. Had exposure to any radiation greater than (>) 15 millisievert (mSv)/year (example, occupational or radiation therapy) within the previous year prior to Baseline imaging.
  4. Has a known to any component of the formulation of TAK-935 or related compounds, or to [18F]MNI-792 or to any of its components.
  5. Clinically significant abnormal findings on brain MRI scan or findings on brain MRI that may interfere with the interpretation of the PET imaging.
  6. Use of any over-the-counter, herbal, or prescription medications or supplements within 30 days prior to baseline imaging.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    TAK-935

    A single dose of TAK-935 600 milligram (mg), oral solution on Day 1 as a starting dose and up to 370 megabecquerel (MBq) (10 millicurie \[mCi\]) of \[18F\]MNI-792 with a mass of up to 5 microgram (mcg), injection intravenously (IV), prior to each PET imaging at Baseline, 45 minutes and 10 hours post-TAK-935 dose. Subsequent dose of TAK-935 oral solution and timing of PET imaging will be based on safety, tolerability and occupancy data from previous level participants.

    Drug: TAK-935 · Drug: [18F]MNI-792 (tracer)

Interventions

06

What researchers measure

Primary outcomes

  1. Cholesterol 24S-Hydroxylase (CH24H) Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 45 Minutes Post-TAK-935 Dose

    CH24H brain enzyme occupancy was obtained by graphical analysis of global occupancy plot. Global occupancy plot was calculated as: total volume of distribution \[VT\] (Baseline) - VT (Day 1) = Occupancy (Day 1) \* (VT \[Baseline\] - non-displaceable volume of distribution \[VND\]), where VT (Baseline) and VT (Day 1) are the total distribution volumes obtained at Baseline and after TAK-935 administration, respectively and VND is the non-displaceable volume of distribution. The occupancy is determined as the slope of the linear regression of the plot, and the VND as the x-intercept. Data was reported only for TAK-935 600 mg because only first two participants were analyzed at 45 minutes post-TAK-935 dose.

    Time frame: 45 minutes post-TAK-935 dose

  2. CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 2 Hours Post-TAK-935 Dose

    CH24H brain enzyme occupancy was obtained by graphical analysis of global occupancy plot. Global occupancy plot was calculated as: VT (Baseline) - VT (Day 1) = Occupancy (Day 1) \* (VT \[Baseline\] - VND), where VT (Baseline) and VT (Day 1) are the total distribution volumes obtained at Baseline and after TAK-935 administration, respectively and VND is the non-displaceable volume of distribution. The occupancy is determined as the slope of the linear regression of the plot, and the VND as the x-intercept.

    Time frame: 2 hours post-TAK-935 dose

  3. CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 10 Hours Post-TAK-935 Dose

    CH24H brain enzyme occupancy was obtained by graphical analysis of global occupancy plot. Global occupancy plot was calculated as: VT (Baseline) - VT (Day 1) = Occupancy (Day 1) \* (VT \[Baseline\] - VND), where VT (Baseline) and VT (Day 1) are the total distribution volumes obtained at Baseline and after TAK-935 administration, respectively and VND is the non-displaceable volume of distribution. The occupancy is determined as the slope of the linear regression of the plot, and the VND as the x-intercept. Data was reported only for TAK-935 600 mg because only first two participants were analyzed at 10 hour post-TAK-935 dose.

    Time frame: 10 hours post-TAK-935 dose

  4. CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 24 Hours Post-TAK-935 Dose

    CH24H brain enzyme occupancy was obtained by graphical analysis of global occupancy plot. Global occupancy plot was calculated as: VT (Baseline) - VT (Day 1) = Occupancy (Day 1) \* (VT \[Baseline\] - VND), where VT (Baseline) and VT (Day 1) are the total distribution volumes obtained at Baseline and after TAK-935 administration, respectively and VND is the non-displaceable volume of distribution. The occupancy is determined as the slope of the linear regression of the plot, and the VND as the x-intercept.

    Time frame: 24 hours post-TAK-935 dose

Secondary outcomes

  1. Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods

    Time frame: At time 0 (just after tracer injection), 1 hour after tracer injection and 2 hours after tracer injection for each post-TAK-935 dosing PET scan period

  2. Percent Change From Baseline in the AUEC24 for Plasma 24S Hydroxycholesterol (24HC)

    Percent change was calculated as = \[(Postdose AUEC24(2) - Baseline AUEC24(2))/Baseline AUEC24(2)\]\*100 percent.

    Time frame: Baseline (Day -1): 1 hour and at multiple timepoints (up to 12 hours) post check in and Day 1: pre-dose and at multiple timepoints (up to 24 hours) post-TAK-935 dose

07

Results

Posted Apr 11, 2017

Participant flow

Participants took part in the study at 1 investigative site in the United States from 01 July 2015 to 04 January 2016.

Participant flow — Overall Study
MilestoneTAK-935 50 mgTAK-935 100 mgTAK-935 200 mgTAK-935 300 mgTAK-935 600 mg
Started22223
Completed22223
Not completed00000

Outcome measures

PrimaryCholesterol 24S-Hydroxylase (CH24H) Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 45 Minutes Post-TAK-935 Dose

CH24H brain enzyme occupancy was obtained by graphical analysis of global occupancy plot. Global occupancy plot was calculated as: total volume of distribution \[VT\] (Baseline) - VT (Day 1) = Occupancy (Day 1) \* (VT \[Baseline\] - non-displaceable volume of distribution \[VND\]), where VT (Baseline) and VT (Day 1) are the total distribution volumes obtained at Baseline and after TAK-935 administration, respectively and VND is the non-displaceable volume of distribution. The occupancy is determined as the slope of the linear regression of the plot, and the VND as the x-intercept. Data was reported only for TAK-935 600 mg because only first two participants were analyzed at 45 minutes post-TAK-935 dose.

Time frame:
45 minutes post-TAK-935 dose
Reported as:
Number · percentage of occupancy
Cholesterol 24S-Hydroxylase (CH24H) Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 45 Minutes Post-TAK-935 Dose
percentage of occupancyTAK-935 600 mg
Participant 1NA
Participant 298
Participant 3NA
PrimaryCH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 2 Hours Post-TAK-935 Dose

CH24H brain enzyme occupancy was obtained by graphical analysis of global occupancy plot. Global occupancy plot was calculated as: VT (Baseline) - VT (Day 1) = Occupancy (Day 1) \* (VT \[Baseline\] - VND), where VT (Baseline) and VT (Day 1) are the total distribution volumes obtained at Baseline and after TAK-935 administration, respectively and VND is the non-displaceable volume of distribution. The occupancy is determined as the slope of the linear regression of the plot, and the VND as the x-intercept.

Time frame:
2 hours post-TAK-935 dose
Reported as:
Number · percentage of occupancy
CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 2 Hours Post-TAK-935 Dose
percentage of occupancyTAK-935 50 mgTAK-935 100 mgTAK-935 200 mgTAK-935 300 mgTAK-935 600 mg
Participant 170799691NA
Participant 264858989NA
Participant 3NANANANA96
PrimaryCH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 10 Hours Post-TAK-935 Dose

CH24H brain enzyme occupancy was obtained by graphical analysis of global occupancy plot. Global occupancy plot was calculated as: VT (Baseline) - VT (Day 1) = Occupancy (Day 1) \* (VT \[Baseline\] - VND), where VT (Baseline) and VT (Day 1) are the total distribution volumes obtained at Baseline and after TAK-935 administration, respectively and VND is the non-displaceable volume of distribution. The occupancy is determined as the slope of the linear regression of the plot, and the VND as the x-intercept. Data was reported only for TAK-935 600 mg because only first two participants were analyzed at 10 hour post-TAK-935 dose.

Time frame:
10 hours post-TAK-935 dose
Reported as:
Number · percentage of occupancy
CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 10 Hours Post-TAK-935 Dose
percentage of occupancyTAK-935 600 mg
Participant 192
Participant 287
Participant 3NA
PrimaryCH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 24 Hours Post-TAK-935 Dose

CH24H brain enzyme occupancy was obtained by graphical analysis of global occupancy plot. Global occupancy plot was calculated as: VT (Baseline) - VT (Day 1) = Occupancy (Day 1) \* (VT \[Baseline\] - VND), where VT (Baseline) and VT (Day 1) are the total distribution volumes obtained at Baseline and after TAK-935 administration, respectively and VND is the non-displaceable volume of distribution. The occupancy is determined as the slope of the linear regression of the plot, and the VND as the x-intercept.

Time frame:
24 hours post-TAK-935 dose
Reported as:
Number · percentage of occupancy
CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 24 Hours Post-TAK-935 Dose
percentage of occupancyTAK-935 50 mgTAK-935 100 mgTAK-935 200 mgTAK-935 300 mgTAK-935 600 mg
Participant 122137946NA
Participant 211NA4727NA
Participant 3NANANANA52
SecondaryPlasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods
Time frame:
At time 0 (just after tracer injection), 1 hour after tracer injection and 2 hours after tracer injection for each post-TAK-935 dosing PET scan period
Reported as:
Number · nanogram per milliliter (ng/mL)
Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods
nanogram per milliliter (ng/mL)TAK-935 50 mgTAK-935 100 mgTAK-935 200 mgTAK-935 300 mgTAK-935 600 mg
Participant 1: PET Scan 1: pre-tracer dose9.1611.315856.26.83
Participant 1: PET Scan 1: 1 hour post-tracer dose3.795.0272.719.4200
Participant 1:PET Scan 1: 2 hours post-tracer dose2.982.4530.312.9379
Participant 1: PET Scan 2: pre-tracer doseNANA14.2NA22.3
Participant 1:PET Scan 2: 1 hour post-tracer doseNANA9.16NA16
Participant 1:PET Scan 2:2 hours post-tracer doseNANA8.08NA14.4
Participant 2: PET Scan 1: pre-tracer dose6.9223.934.850.9569
Participant 2: PET Scan 1: 1 hour post-tracer dose2.9712.316.815.7257
Participant 2:PET Scan 1: 2 hours post-tracer dose1.956.467.5214.690.8
Participant 2: PET Scan 2: pre-tracer doseNA1.83NANA7.99
Participant 2:PET Scan 2: 1 hour post-tracer doseNA1.28NANA6.27
Participant 2:PET Scan 2:2 hours post-tracer doseNANANANA5.12
Participant 3: PET Scan 1: pre-tracer doseNANANANA589
Participant 3: PET Scan 1: 1 hour post-tracer doseNANANANA236
Participant 3:PET Scan 1: 2 hours post-tracer doseNANANANA155
Participant 3: PET Scan 2: pre-tracer doseNANANANA3.04
Participant 3: PET Scan 2: 1 hour post-tracer doseNANANANA2.58
Participant 3:PET Scan 2: 2 hours post-tracer doseNANANANA2.24
SecondaryPercent Change From Baseline in the AUEC24 for Plasma 24S Hydroxycholesterol (24HC)

Percent change was calculated as = \[(Postdose AUEC24(2) - Baseline AUEC24(2))/Baseline AUEC24(2)\]\*100 percent.

Time frame:
Baseline (Day -1): 1 hour and at multiple timepoints (up to 12 hours) post check in and Day 1: pre-dose and at multiple timepoints (up to 24 hours) post-TAK-935 dose
Reported as:
Number · percent change
Percent Change From Baseline in the AUEC24 for Plasma 24S Hydroxycholesterol (24HC)
percent changeTAK-935 50 mgTAK-935 100 mgTAK-935 200 mgTAK-935 300 mgTAK-935 600 mg
Participant 1-6.79-14.82-10.50-12.41-7.23
Participant 2-13.38-15.04-9.30-18.55-12.79
Participant 3NANANANA-6.81

Adverse events

Collected over Baseline up to Day 28. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Baseline [18F]MNI-792—0/11 (0%)1/11 (9.1%)
TAK-935 50 mg—0/2 (0%)1/2 (50%)
TAK-935 100 mg—0/2 (0%)1/2 (50%)
TAK-935 200 mg—0/2 (0%)1/2 (50%)
TAK-935 300 mg—0/2 (0%)1/2 (50%)
TAK-935 600 mg—0/3 (0%)1/3 (33.3%)
Most frequent other events
Most frequent other events
EventBaseline [18F]MNI-792TAK-935 50 mgTAK-935 100 mgTAK-935 200 mgTAK-935 300 mgTAK-935 600 mg
TinnitusEar and labyrinth disorders0/111/20/20/20/20/3
Catheter site haemorrhageGeneral disorders0/110/20/21/20/20/3
PresyncopeNervous system disorders0/10/21/20/20/20/3
HypertensionVascular disorders0/110/20/20/21/20/3
Blood creatine phosphokinase increasedInvestigations0/110/20/20/20/21/3
SyncopeNervous system disorders1/110/20/20/20/20/3

Baseline characteristics

Safety analysis set included all participants who were enrolled and received investigational drug (\[18F\]MNI-792 or TAK-935).

Age, Continuous
Age, Continuous(years)TAK-935 50 mgTAK-935 100 mgTAK-935 200 mgTAK-935 300 mgTAK-935 600 mgTotal
Mean40.0 ± 7.0725.5 ± 2.1242.0 ± 2.8348.5 ± 2.1236.7 ± 6.1138.4 ± 8.48
Sex/Gender, Customized
Sex/Gender, Customized(participants)TAK-935 50 mgTAK-935 100 mgTAK-935 200 mgTAK-935 300 mgTAK-935 600 mgTotal
Male2222311
Region of Enrollment
Region of Enrollment(participants)TAK-935 50 mgTAK-935 100 mgTAK-935 200 mgTAK-935 300 mgTAK-935 600 mgTotal
United States2222311
Ethnicity
Ethnicity(participants)TAK-935 50 mgTAK-935 100 mgTAK-935 200 mgTAK-935 300 mgTAK-935 600 mgTotal
Hispanic or Latino120014
Not Hispanic or Latino102227
Race
Race(participants)TAK-935 50 mgTAK-935 100 mgTAK-935 200 mgTAK-935 300 mgTAK-935 600 mgTotal
Black or African American212016
White010225
Height
Height(centimeter (cm))TAK-935 50 mgTAK-935 100 mgTAK-935 200 mgTAK-935 300 mgTAK-935 600 mgTotal
Mean171.5 ± 4.95181.5 ± 3.54177.0 ± 4.24180.0 ± 0.00183.0 ± 16.09179.0 ± 8.69
Weight
Weight(kilogram (kg))TAK-935 50 mgTAK-935 100 mgTAK-935 200 mgTAK-935 300 mgTAK-935 600 mgTotal
Mean86.05 ± 7.28393.60 ± 10.74879.40 ± 12.86987.05 ± 5.16284.83 ± 23.69286.06 ± 13.009
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram per square meter (kg/m^2))TAK-935 50 mgTAK-935 100 mgTAK-935 200 mgTAK-935 300 mgTAK-935 600 mgTotal
Mean29.22 ± 0.78928.37 ± 2.15725.46 ± 5.32726.87 ± 1.59324.95 ± 4.27526.79 ± 3.212
08

Study locations

1 site
  • New Haven, Connecticut, United States
09

References and documents

Publications

  • Constantinescu CC, Brown T, Wang S, Yin W, Barret O, Jennings D, Tauscher J. Clinical Characterization of [18F]T-008, a Cholesterol 24-Hydroxylase PET Ligand: Dosimetry, Kinetic Modeling, Variability, and Soticlestat Occupancy. J Nucl Med. 2023 Dec 1;64(12):1972-1979. doi: 10.2967/jnumed.123.265912. PubMed 37770111 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2015, a primary completion of Dec 2015 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2015
First posted
Jul 14, 2015
Start
Jul 2015
Primary completionActual
Dec 2015
CompletionActual
Jan 2016
Results first posted
Apr 11, 2017
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02497235
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jul 14, 2015
Start date
Jul 2015
Primary completion
Dec 2015
Completion
Jan 2016
Results posted
Apr 11, 2017
Last update
Sep 15, 2026

Study contacts

Medical Director
study director · Takeda (Note: This product was divested to Mistrau Bio, Inc. in 2026)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Soticlestat · Spinosad

Start the discussion